• Explore /
  • Poster
  • / A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).

A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).

Abstract Poster

Authors

Michael Pishvaian

Michael J. Pishvaian

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Michael J. Pishvaian , Hongkun Wang , Brandon George Smaglo , Jennifer Gao , Laura Macke , Erica Redmond , Eva Camilla Andersson Permaul , Supti Sen , Damian L. McCarthy , Bhaskar Kallakury , Stephen V. Liu , Aiwu Ruth He , Jimmy J. Hwang , Sandra M. Swain , John Marshall , Paula Raffin Pohlmann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT01522989

Citation

J Clin Oncol 34, 2016 (suppl; abstr 2589)

DOI

10.1200/JCO.2016.34.15_suppl.2589

Abstract #

2589

Poster Bd #

289

Abstract Disclosures

Similar Posters

First Author: Akshara Singareeka Raghavendra

First Author: Jeffrey R. Infante

First Author: Sonia Pernas

First Author: Melinda L. Telli